SCHEMBL12529574

SCHEMBL12529574

COc1cc(Nc2ncc3ccn(-c4ccnc(C)c4)c3n2)cc(OC)c1OC

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 20/20 0.80
▸ JAK2 O60674 2/20 0.72
▸ AURKA O14965 1/20 0.72
▸ DAPK3 O43293 1/20 0.72
▸ PAK4 O96013 1/20 0.72
▸ ABL1 P00519 1/20 0.72
▸ NTRK1 P04629 1/20 0.72
▸ LCK P06239 1/20 0.72
▸ FYN P06241 1/20 0.72
▸ CSF1R P07333 1/20 0.72
▸ RET P07949 1/20 0.72
▸ IGF1R P08069 1/20 0.72
▸ MET P08581 1/20 0.72
▸ PDGFRB P09619 1/20 0.72
▸ FGFR1 P11362 1/20 0.72
▸ PDGFRA P16234 1/20 0.72
▸ PRKACA P17612 1/20 0.72
▸ FLT1 P17948 1/20 0.72
▸ LTK P29376 1/20 0.72
▸ KDR P35968 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12529123 0.89 PTK2 (1.00) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12529148 0.88 PTK2 (1.00) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12528966 0.86 PTK2 (0.80) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12529526 0.86 PTK2 (0.80) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12528959 0.86 PTK2 (0.84) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12528978 0.86 PTK2 (1.00) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12528928 0.85 PTK2 (1.00) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12529108 0.85 PTK2 (1.00) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12529156 0.83 PTK2 (0.78) PTK2JAK2AURKADAPK3PAK4
SCHEMBL12529133 0.82 PTK2 (0.77) PTK2JAK2AURKADAPK3PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968557-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs NOVARTIS AG (CH) 2011-06-28 — — US disclosed
Send feedback